BMS Expands Manufacturing Agreement with Lonza
Bristol-Myers Squibb announced a multi-year expansion of its biologics manufacturing agreement with Lonza.
Bristol-Myers Squibb (BMS) announced on Oct. 30, 2014 that it would expand its existing biologics manufacturing agreement to include the production of commercial quantities of a second BMS biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire.
BMS and Lonza have collaborated since 2003 to produce commercial supplies of a biologics medicine. Lonza also produces clinical supplies of an investigational biologics medicine for BMS.
Source: Bristol-Myers Squibb
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
